Abstract
Positron Emission Tomography (PET) offers an exciting opportunity to monitor key pathways involved in malignant transformation due to the ability to radiolabel and image the behaviour of biological probes. In this review, we will describe how PET can use various radiolabelled compounds to monitor various targets including ligand-receptor interactions using 16α-[18F]fluoro-17β-oestradiol (FES) pathways involved in metabolism with [18F]fluorodeoxy-glucose ([18F]FDG), 11C-methyl-choline for signal transduction, cell cycle and proliferation with 2-[11C]thymidine, cell death using [124I]annexin V, [11C]colchicine for drug resistance and angiogenesis using [124I]anti-VEGF.
Keywords: Pharmacodynamics, Radiolabelled, Anticancer Drugs, 11C-methyl-choline, ligand-receptor, Positron Emission Tomography (PET)
Current Pharmaceutical Design
Title: Pharmacodynamics of Radiolabelled Anticancer Drugs for Positron Emission Tomography
Volume: 9 Issue: 11
Author(s): O. Clyde Hutchinson, David R. Collingridge, Henryk Barthel, Pat. M. Price and Eric O. Aboagye
Affiliation:
Keywords: Pharmacodynamics, Radiolabelled, Anticancer Drugs, 11C-methyl-choline, ligand-receptor, Positron Emission Tomography (PET)
Abstract: Positron Emission Tomography (PET) offers an exciting opportunity to monitor key pathways involved in malignant transformation due to the ability to radiolabel and image the behaviour of biological probes. In this review, we will describe how PET can use various radiolabelled compounds to monitor various targets including ligand-receptor interactions using 16α-[18F]fluoro-17β-oestradiol (FES) pathways involved in metabolism with [18F]fluorodeoxy-glucose ([18F]FDG), 11C-methyl-choline for signal transduction, cell cycle and proliferation with 2-[11C]thymidine, cell death using [124I]annexin V, [11C]colchicine for drug resistance and angiogenesis using [124I]anti-VEGF.
Export Options
About this article
Cite this article as:
Hutchinson Clyde O., Collingridge R. David, Barthel Henryk, Price M. Pat. and Aboagye O. Eric, Pharmacodynamics of Radiolabelled Anticancer Drugs for Positron Emission Tomography, Current Pharmaceutical Design 2003; 9 (11) . https://dx.doi.org/10.2174/1381612033455251
DOI https://dx.doi.org/10.2174/1381612033455251 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
HSV-1-Derived Recombinant and Amplicon Vectors for Gene Transfer and Gene Therapy
Current Gene Therapy Recent Advances and Approaches in Targeting Apoptosis Signaling Pathways for Anti-Cancer Therapeutics
Current Cancer Therapy Reviews The ErbB Receptors and their Ligands in Cancer: An Overview
Current Drug Targets Biology of Transforming Growth Factor-β Signaling
Current Pharmaceutical Biotechnology Contrast Functions of αA- and αB-Crystallins in Cancer Development
Current Molecular Medicine Recent Patents on Novel P2X7 Receptor Antagonists and their Potential for Reducing Central Nervous System Inflammation
Recent Patents on CNS Drug Discovery (Discontinued) NEDD4: A Promising Target for Cancer Therapy
Current Cancer Drug Targets A Synopsis of Nano-Technological Approaches Toward Anti-Epilepsy Therapy: Present and Future Research Implications
Current Drug Metabolism Bevacizumab and Angiogenesis Inhibitors in the Treatment of CNS Metastases: The Road less Travelled
Current Molecular Pharmacology Design, Preparation and Characterization of Modular Squalene-based Nanosystems for Controlled Drug Release
Current Topics in Medicinal Chemistry Progress on Multi-Modality Molecular Imaging
Current Medical Imaging Genomic Context Vectors and Artificial Chromosomes for Cystic Fibrosis Gene Therapy
Current Gene Therapy Targeting Histone Deacetylases for the Treatment of Immune, Endocrine & Metabolic Disorders
Endocrine, Metabolic & Immune Disorders - Drug Targets Molecular Fundamentals and Rationale for Immunotherapy in Metastatic Melanoma Treatment
Clinical Cancer Drugs Withdrawal Notice: Application of Nanomaterials in Development of Electrochemical Sensors and Drug Delivery Systems for Anticancer Drugs
Current Drug Delivery Role of Unani Medicines in Cancer Control and Management
Current Drug Therapy Structure, Function and Biological Relevance of Prolyl Oligopeptidase
Current Protein & Peptide Science MiRNA-29: A microRNA Family with Tumor-Suppressing and Immune-Modulating Properties
Current Molecular Medicine Search and Rescue: Identification of Cannabinoid Actions Relevant for Neuronal Survival and Protection
Current Neuropharmacology Recent Development in Nano-Sized Dosage Forms of Plant Alkaloid Camptothecin-Derived Drugs
Recent Patents on Anti-Cancer Drug Discovery